 |
|
|
|
 |
|
|
| Article 1 to 4 out of 4 concerning Santaris Pharma A/S
|
-
Santaris Pharma begins human clinical testing of the world's first medicine targeted at a human microRNA
(05/30/2008)
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection
Santaris Pharma announced that it has commenced a Phase I human volunteer trial of SPC3649 (LNA-antimiRTM-122), the world's first microRNA medicine to be tested in man, according to the company. The study is being conducted by PhaseOneTrials A/S, ...
-
Nature publishes study by Santaris Pharma scientists and collaborators: LNA-mediated microRNA silencing in non-human primates
(03/28/2008)
Santaris Pharma announced the publication in Nature of a peer-reviewed study entitled "NA-mediated microRNA silencing in non-human primates". The paper is the first demonstration of microRNA silencing in non-human primates, providing an important ...
-
Santaris Pharma's HIF-1 alpha antagonist begins second phase 1 study against solid tumours and lymphoma
(11/06/2007)
Enzon Pharmaceuticals, Inc. has initiated a second clinical study of EZN-2968 to evaluate additional dosing schedule
Santaris Pharma A/S announced the initiation of an open-label, non-randomized Phase 1 study with its HIF-1 alpha antagonist (EZN-2968) licensed outside Europe in 2006 to Enzon Pharmaceuticals, Inc. USA. The study is designed to evaluate the safety, ...
-
GLSV invests in Santaris Pharma A/S
(03/17/2006)
Global Life Science Ventures (GLSV) announced an investment in Santaris Pharma A/S in a Series B financing round totalling EUR40 million, as part of a syndicate led by ABN AMRO Capital Life Science and also including BankInvest, Novo Ventures, LD ...
Additional information
Santaris Pharma A/S
Hørsholm, Denmark
Company
|
|
|
|
|
|
Top
